MeOmics Precision Medicine

MeOmics Precision Medicine is a biotechnology company developing a precision psychiatry platform that combines genomics, phenomics, and stem cell-based cellular assays to generate biomarkers for severe mental illness.

Patient-derived neurons, stimulated via multi-electrode array recording, produce electrophysiological signatures used to stratify patients by biological subtype and predict drug response in vitro.

The platform is designed to support pharmaceutical drug discovery for conditions including schizophrenia and bipolar disorder, reducing attrition in clinical development.